Boehringer Ingelheim Venture Fund led a funding round in ArrePath.

Boehringer Ingelheim Venture Fund, a corporate venture capital firm, led a funding round in ArrePath, a biotechnology company, with participation from Insight Partners, Innospark, Nor’easter Ventures, and AB Magnitude. Financial terms were not disclosed. “We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magnitude, to ArrePath. This raise, in combination with our recently announced non-dilutive funding awards from PACE and CARB-X, enables ArrePath to advance our lead program, AP-001, towards development candidate nomination and eventual Phase 1 studies. In addition, the new funding will support expansion of our novel compounds active against non-tuberculous mycobacteria,” Kevin Krause, ArrePath President and CEO.